Mireskandari Alidad reported grant involving 80,000 derivative units of Niki BioSolutions, Inc. at $0.00 for $0 on Jul 22, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
President & COO
President & COO
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
80,000Stock Options
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
80,000Direct
Trade date
Jul 22, 2026Grant
Filed
Nov 17, 2026, 3:50 PM ET118-day reporting delay
Accession
0001213900-26-121376Code A · Transaction 402880
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jul 22, 2026Grant20,000$0.00$0Trade 402879
Jul 22, 2026Option exercise20,000——Trade 402878
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 118 calendar days after the transaction date.

NIKI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NIKI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Each RSU represents a contingent right to receive, upon settlement, one share of Common Stock. F2: On July 22, 2026, the reporting person was granted 20,000 RSUs, which vested on that same date. F3: The options vest as follows: (i) 40,000 options vest in eight equal quarterly installments; (ii) 5,000 options vest upon completion and publication of the clinical validation study of CogniMIR(R) to meet CLIA requirements; (iii) 10,000 options vest upon the Company entering into a biopharmaceutical services, collaboration or partnership agreement resulting in proceeds to the Company of at least $250,000; (iv) 5,000 options vest upon the Company generating $1,000,000 in revenue; (v) 10,000 options vest upon completion of capital raises totaling $5,000,000; and (vi) 10,000 options vest upon a 100% increase in the Company's stock price following the closing of the merger that occurred in July 2026.